clinical trial · NCT06926491
Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）
Kyowa Kirin Co., Ltd.·phase3·recruiting·n = 6
AchondroplasiaKK8398
brief summary
This trial will evaluate the efficacy of KK8398 on annualized height velocity after 52 weeks of repeated administration of KK8398 to patients with achondroplasia
started
Dec 1, 2024
primary completion
May 31, 2029
completion
May 31, 2031
last updated
Apr 29, 2025
official title
A Multicenter, Open-label, Single-arm, Phase 3 Study of KK8398 (Infigratinib) in Patients With Achondroplasia (AOBA Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol